Yang Rui-fang, Li Chun-ming, Qiu Hai-rong, Lu Hua, Wu Han-xin, Xu Jia-ren, Zhang Peng, Li Jian-yong, Chen Li-juan
Tianjin Medical University Cancer Institute and Hospital, Tianjin Cancer Research Institute, Tianjin, People's Republic of China.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2011 Dec;28(6):686-9. doi: 10.3760/cma.j.issn.1003-9406.2011.06.020.
To investigate the prevlance of 1q21 amplification in patients with multiple myeloma (MM) and its correlation with the progression and prognosis of the disease.
1q21 amplification was detected in 48 patients with MM using cytoplasmic light chain immunofluorescence with fluorescence in situ hybridization analysis (cIg-FISH) and interphase fluorescence in situ hybridization (I-FISH) analysis combined with CD138 immunomagnetic cell sorting (MACS).
1q21 amplification (≥ 3 red signals) was detected in 26/48(54.2%) cases by cIg-FISH and 31/48 (64.6%) cases by I-FISH combined with CD138 MACS. There was a good consistency between the two methods (P>0.05). The mortality of patients with 1q21 amplification was significantly higher than those without (P< 0.05). No significant difference was detected in terms of sex, age, Durie-Salmon stage, subgroup and international staging system (ISS) stage between patients with 1q21 amplification and those without (P>0.05).
The frequency of 1q21 amplification in MM is high. There was also an association between the amplification and poor prognosis. cIg-FISH is consistent with CD138 MACS combined with I-FISH.
探讨多发性骨髓瘤（MM）患者中1q21扩增的发生率及其与疾病进展和预后的相关性。
采用胞质轻链免疫荧光与荧光原位杂交分析（cIg-FISH）以及间期荧光原位杂交（I-FISH）分析联合CD138免疫磁珠细胞分选（MACS）技术，对48例MM患者进行1q21扩增检测。
通过cIg-FISH检测，26/48（54.2%）例患者存在1q21扩增（≥3个红色信号）；通过I-FISH联合CD138 MACS检测，31/48（64.6%）例患者存在1q21扩增。两种方法之间具有良好的一致性（P>0.05）。1q21扩增患者的死亡率显著高于无扩增患者（P<0.05）。1q21扩增患者与无扩增患者在性别、年龄、Durie-Salmon分期、亚组及国际分期系统（ISS）分期方面均未检测到显著差异（P>0.05）。
MM中1q21扩增的频率较高。扩增与不良预后之间也存在关联。cIg-FISH与CD138 MACS联合I-FISH结果一致。
Zotero 插件